JNJ-5207852

JNJ-5207852 is a histamine antagonist selective for the H₃ subtype. It has stimulant and nootropic effects in animal studies,<ref name="pmid15466448">Barbier AJ, Berridge C, Dugovic C, et al.,

 Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist, 
 Br. J. Pharmacol., 
 
 Vol. 143(Issue: 5),
 pp. 649–61,
 DOI: 10.1038/sj.bjp.0705964,
 PMID: 15466448,
 PMC: 1575430,</ref> and has been suggested as a possible treatment for memory defects associated with epilepsy.<ref>Jia F, Kato M, Dai H, Xu A, Okuda T, Sakurai E, Okamura N, Lovenberg TW, Barbier A, Carruthers NI, Iinuma K, Yanai K. Effects of histamine H(3) antagonists and donepezil on learning and mnemonic deficits induced by pentylenetetrazol kindling in weanling mice. Neuropharmacology. 2006 Mar;50(4):404-11. PMID 16310812</ref> JNJ-5207852 itself did not progress to clinical development due to poor pharmacokinetic characteristics, but the related compound JNJ-17216498 is currently in Phase II clinical trials for the treatment of narcolepsy.<ref name="pmid18469850">Esbenshade TA, Browman KE, Bitner RS, Strakhova M, Cowart MD, Brioni JD, 
 The histamine H3 receptor: an attractive target for the treatment of cognitive disorders, 
 Br. J. Pharmacol., 
 
 Vol. 154(Issue: 6),
 pp. 1166–81,
 DOI: 10.1038/bjp.2008.147,
 PMID: 18469850,
 PMC: 2483387,</ref>

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

Stub icon

   This article is a  stub. You can help WikiMD by expanding it!